It is reported that Technimed’s magnetic resonance imaging (MRI) technology and product Oxy-17 effectively renders an unaltered MRI scanner into a positron emission tomography (PET), PET/CT like metabolic imager using ultra pure oxygen, isotopically enriched and naturally occurring in atmospheric air, delivered to target tissue of interest. The ability to follow cellular respiration in real-time using an unaltered MRI in these patients is a paradigm shift in the management of these patients, noted Sanguine.
As part of the agreement, Sanguine has agreed to license the technology and know-how for PHER-02 to Rockland for use and further development by Rockland Technimed in conjunction with its imaging technology.
Thomas Drees, CEO of Sanguine, said: “We concluded that the best way to move both technologies and products ahead was to enter into a licensing arrangement that will accomplish that. Our team feels that a relationship with Rockland Technimed provides us with a unique opportunity to move the company’s focus of PHER-O2 into intravenous use.”